Archived
This content is available here strictly for research, reference, and/or recordkeeping and as such it may not be fully accessible. If you work or study at University of Kentucky and would like to request an accessible version, please use the SensusAccess Document Converter.
Abstract
Introduction: Large cell neuroendocrine carcinomas (LCNEC) are a group of rare high grade neuroendocrine tumors that often behave clinically like small cell carcinoma (SCLC) and are treated as such. No major advancement in the management of these tumors has occurred in the last 30 years.
Methods: We present a case series of three cases from Markey Cancer center along with a review of 13 published cases in the literature wherein immune-checkpoint inhibitors were utilized in the management of LCNEC.
Results: Immune-checkpoint inhibitors might have clinical activity in LCNEC.
Conclusion: Role of immune-checkpoint inhibitors should be explored in prospective LCNEC clinical trials. We summarize current evidence regarding use of immune checkpoint inhibitors in the treatment of LCNEC.
Document Type
Article
Publication Date
3-6-2018
Digital Object Identifier (DOI)
https://doi.org/10.18632/oncotarget.24553
Repository Citation
Chauhan, Aman; Arnold, Susanne; Kolesar, Jill M.; Thomas, Hala Elnakat; Evers, B. Mark; and Anthony, Lowell B., "Immune Checkpoint Inhibitors in Large Cell Neuroendocrine Carcinoma: Current Status" (2018). Markey Cancer Center Faculty Publications. 110.
https://uknowledge.uky.edu/markey_facpub/110
Included in
Cell and Developmental Biology Commons, Neuroscience and Neurobiology Commons, Oncology Commons
Notes/Citation Information
Published in Oncotarget, v. 9, no. 18, p. 14738-14740.
Copyright: Chauhan et al.
This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.